阿达木单抗与依奇珠单抗治疗银屑病关节炎的缓解比较与预测因素:AIRE多中心研究
AIRE多中心队列研究比较阿达木单抗与依奇珠单抗在真实世界银屑病关节炎患者中的有效性,纳入437例患者随访12个月。两组DAPSA改善轨迹及12个月DAPSA缓解/MDA概率无显著差异,依奇珠单抗3个月时PASI早期下降更明显。缓解主要与男性、无甲银屑病、较高PASI、较少既往bDMARD及较好功能状态相关。
要点
- 阿达木单抗与依奇珠单抗12个月关节结局相似,依奇珠单抗皮肤应答更早。
- DAPSA缓解与MDA主要预测因素:男性、无甲银屑病、较高PASI、较少既往bDMARD。
- 真实世界PsA治疗应个体化达标治疗,基线特征影响缓解概率。
核心结论
- 真实世界中阿达木单抗与依奇珠单抗提供相似的12个月关节结局,依奇珠单抗皮肤应答更快。
- 基线人口学与临床特征影响缓解机会,支持PsA个体化达标治疗。
研究设计与样本
- AIRE为多中心队列研究,比较阿达木单抗与依奇珠单抗在真实世界PsA人群中的有效性。
- 共纳入437例患者,42%接受阿达木单抗,57%接受依奇珠单抗。
- 主要结局采用混合效应模型比较12个月内DAPSA与PASI,缓解结局采用时间依赖Cox模型校正混杂因素。
主要发现
- 两组DAPSA评分均改善,随时间DAPSA轨迹的组间差异不显著。
- 12个月时达到DAPSA缓解或MDA的概率无药物差异。
- 两组PASI改善相似,但依奇珠单抗3个月时较基线的早期下降更明显。
- DAPSA缓解和MDA主要与男性、无甲银屑病、较高PASI、较少既往bDMARD及较好功能状态相关。
- 基线时阿达木单抗组主要表现为轴向和指甲受累,依奇珠单抗组多为bDMARD经治且CRP更高、功能状态更差。
关键数值与推荐
- 主要结局为12个月内DAPSA与PASI的混合效应模型比较。
- 缓解结局包括DAPSA缓解和MDA,采用时间依赖Cox模型校正混杂因素分析。
临床怎么用
- 对关节结局预期相似时,可结合皮肤应答速度、基线特征及既往bDMARD史个体化选择阿达木单抗或依奇珠单抗。
- 基线男性、无甲银屑病、较高PASI、较少既往bDMARD及较好功能状态提示缓解概率更高,可用于达标治疗分层。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Tumour necrosis factor α (TNFi) and interleukin 17 (IL-17) inhibitors have demonstrated efficacy and safety in psoriatic arthritis (PsA) therapy through head-to-head randomised controlled trials, but evidence from real-world clinical practice (RWE) remains limited. METHODS: Adalimumab vs Ixekizumab Real-world Effectiveness is a multicentre cohort study, aimed at comparing the effectiveness of these drugs in a 'real-world' PsA population. The primary outcome consisted of mixed-effects models comparing Disease Activity in Psoriatic Arthritis (DAPSA) and Psoriasis Areas and Severity Index (PASI) over 12 months in both treatment groups. Remission outcomes (DAPSA; Minimal Disease Activity (MDA)) were analysed using time-dependent Cox models adjusted for confounders. RESULTS: A total of 437 patients (42% on adalimumab (ADA); 57% on ixekizumab (IXE)) were enrolled. At baseline, the ADA group mainly showed axial and nail involvement, while the IXE group was mostly biologic disease-modifying antirheumatic drug (bDMARD)-experienced and had higher C reactive protein levels and worse functional status.The DAPSA score improved in both groups, and between-treatment differences in DAPSA pathways over time were not significant. Probabilities of achieving DAPSA remission or MDA did not differ by drug at 12 months. PASI improved similarly in both groups, but IXE showed a greater early reduction from baseline at 3 months. DAPSA remission and MDA were primarily associated with male sex, absence of nail psoriasis, higher PASI, fewer prior bDMARDs and better functional status. CONCLUSIONS: This RWE study showed that ADA and IXE provide similar 12-month joint outcomes, while IXE showed a faster skin response. Baseline demographic and clinical features affect the chance of remission, highlighting the importance of personalised treat-to-target approaches in PsA.
引用
- Paci V, Zabotti A, Fontanarosa A, et al. Comparative effectiveness and predictors of remission between adalimumab and ixekizumab in patients with psoriatic arthritis: findings from the 'AIRE' multicentre study. RMD Open. 2026. PMID: 41876147. doi:10.1136/rmdopen-2025-006667
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。